首页> 外文期刊>Journal of enzyme inhibition and medicinal chemistry. >Synthesis and biological evaluation of novel ( E )- N' -benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening
【24h】

Synthesis and biological evaluation of novel ( E )- N' -benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening

机译:通过基于片段的虚拟筛选的新型(E) - N'-苄基肼作为新型C-Met抑制剂的合成和生物学评价

获取原文
           

摘要

C-Met plays a crucial role in the development and progression of neoplastic disease. Type II c-Met inhibitors recognise the inactive DFG-out conformation of the kinase, result in better anti-tumour effects due to synergistic effect against the other kinases. According to our previous works, an (E)-N'-benzylidene group was selected as the initial fragment. Two series of (E)-N'-benzylidene hydrazides were designed by fragment growth method. The inhibitory activities were in?vitro investigated against c-Met and VEGFR-2. Compound 10b exhibited the most potent inhibitory activity against the c-Met inhibitor (ICsub50/sub = 0.37?nM). Compound 11b exhibited multi-target c-Met kinase inhibitory activity as a potential type II c-Met inhibitor (ICsub50/sub = 3.41?nM against c-Met; 25.34?nM against VEGFR-2). The two compounds also demonstrate the feasibility of fragment-based virtual screening method for drug discovery.
机译:C-MET在肿瘤疾病的开发和进展中起着至关重要的作用。 II型C-MET抑制剂识别激酶的无活性DFG-OUT构象,导致由于对其他激酶的协同效应而导致更好的抗肿瘤作用。根据我们之前的作用,选择(E)-N'-苄基组作为初始片段。通过片段生长方法设计了两种(e)-N'-苄基肼肼。抑制性活性在含有C-Met和VEGFR-2的体外。化合物10b对C-Met抑制剂的最有效的抑制活性表现出(IC 50 =0.37≤nm)。化合物11b表现出多目标C-Met激酶抑制活性,作为潜在的II型C-Met抑制剂(IC 50 = 3.41Δnm,对抗VEGFR-2)。两种化合物还证明了基于片段的虚拟筛选方法的可行性进行药物发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号